This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.
Clinical trial NCT05438810 · UNKNOWN
Trial details
- NCT number
- NCT05438810
- Sponsor
- Ahon Pharmaceutical Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-01-18
- Primary completion
- 2024-02-18
- Enrollment
- 312
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.